Outpatient Delivery of Step‐Up Doses to Rapidly Initiate Monthly Doses of Bispecific Antibodies in Multiple Myeloma

In conclusion, using outpatient step-up dosing followed by planned de-escalation to monthly doses of BsAbs in responding patients with MM is feasible, safe, and effective, and may improve access to this novel therapy.